← Back to Screener
Outlook Therapeutics, Inc. Common Stock (OTLK)
Price$0.37
Favorite Metrics
Price vs S&P 500 (26W)-78.65%
Price vs S&P 500 (4W)7.56%
Market Capitalization$38.71M
All Metrics
Book Value / Share (Quarterly)$0.82
P/TBV (Annual)13.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-22.93%
Cash Flow / Share (Quarterly)$-0.86
Price vs S&P 500 (YTD)-80.51%
Net Profit Margin (TTM)-1338.75%
EPS (TTM)$-2.71
10-Day Avg Trading Volume5.68M
EPS Excl Extra (TTM)$-2.71
Revenue Growth (5Y)-13.86%
EPS (Annual)$-1.79
ROI (Annual)-335.84%
Gross Margin (Annual)4.05%
Net Profit Margin (5Y Avg)-1724.56%
Cash / Share (Quarterly)$0.13
ROA (Last FY)-259.89%
EBITD / Share (TTM)$-2.37
Operating Margin (TTM)-1046.20%
Cash Flow / Share (Annual)$-2.87
P/B Ratio3.69x
P/B Ratio (Quarterly)26.67x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)44.30x
Net Interest Coverage (TTM)-190.32x
ROA (TTM)-525.54%
EV / EBITDA (TTM)3.29x
EPS Incl Extra (Annual)$-1.79
Current Ratio (Annual)0.63x
Quick Ratio (Quarterly)0.18x
3-Month Avg Trading Volume5.16M
52-Week Price Return-74.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.02
P/S Ratio (Annual)27.38x
Asset Turnover (Annual)0.48x
52-Week High$3.39
Operating Margin (5Y Avg)-1772.52%
EPS Excl Extra (Annual)$-1.79
26-Week Price Return-71.76%
Quick Ratio (Annual)0.35x
13-Week Price Return-29.15%
Total Debt / Equity (Annual)1.25x
Current Ratio (Quarterly)0.35x
Enterprise Value$66.69
Revenue / Share Growth (5Y)-72.88%
Asset Turnover (TTM)0.07x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4525.99%
Cash / Share (Annual)$0.63
3-Month Return Std Dev134.05%
Net Income / Employee (TTM)$-6
ROE (Last FY)-756.01%
Net Interest Coverage (Annual)-267.68x
EPS Basic Excl Extra (Annual)$-1.79
Total Debt / Equity (Quarterly)3.04x
EPS Incl Extra (TTM)$-2.71
ROI (TTM)-163.27%
P/S Ratio (TTM)130.11x
Pretax Margin (5Y Avg)-1775.19%
Revenue / Share (Annual)$0.04
Tangible BV / Share (Annual)$0.04
Price vs S&P 500 (52W)-109.12%
Year-to-Date Return-76.58%
5-Day Price Return46.25%
EPS Normalized (Annual)$-1.79
ROA (5Y Avg)-217.13%
Net Profit Margin (Annual)-4416.21%
Month-to-Date Return79.79%
Cash Flow / Share (TTM)$-0.25
EBITD / Share (Annual)$-1.83
Operating Margin (Annual)-4744.24%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-2965.91%
LT Debt / Equity (Quarterly)2.02x
EPS Basic Excl Extra (TTM)$-2.71
P/B Ratio (Annual)31.58x
Pretax Margin (TTM)-1338.75%
Book Value / Share (Annual)$0.77
Price vs S&P 500 (13W)-31.53%
Beta0.68x
Revenue / Share (TTM)$0.00
ROE (TTM)-415.51%
52-Week Low$0.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.82
3.90
3.90
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OTLKOutlook Therapeutics, Inc. Common Stock | 130.11x | — | — | — | $0.37 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Outlook Therapeutics develops ONS-5010/LYTENAVA (bevacizumab-gamma), a monoclonal antibody for ophthalmic diseases. LYTENAVA has received marketing approval in the European Union and United Kingdom for wet age-related macular degeneration treatment. The company is pursuing additional indications for its lead therapy as a first-line anti-VEGF option.